Table 2:

Summary of Apoptosis Time Course Data Obtained from Imaging Experiments.

Reference	Treatment	Model	Radiotracer	Curve Type	FWHM (h)	Time to Max (h)	Fold Change at Max	SD at Max (%)
9	Cyclophosphamide	Mice	[18F]F-ICMT-11	Unimodal	>36	24	1.99	36.9
9	Birinapant	Mice	[18F]F-ICMT-11	Unimodal	15	6	1.54	42.7
42	Doxorubicin	Mice	[18F]F-Annexin V	Unimodal	97	72	1.76	6.9
36	Paclitaxel	Mice	[111In]In-DTPA-PEG-Annexin V	Monotonic	N/A	96	1.75	12.8
36	C225	Mice	[111In]In-DTPA-PEG-Annexin V	Unimodal	24.8	24	1.14	21.3
31	5-FU	Mice	[99mTc]Tc-(CO)3-His-Annexin A5	Bimodal	25.4	8	1.52	9.1
31	Irinotecan	Mice	[99mTc]Tc-(CO)3-His-Annexin A5	Unimodal	24.4	24	1.56	1.3
31	Oxaliplatin	Mice	[99mTc]Tc-(CO)3-His-Annexin A5	Unimodal	27.7	24	1.79	7.6
31	Bevacizumab	Mice	[99mTc]Tc-(CO)3-His-Annexin A5	No increase	3.7	24	1.07	14.1
31	Panitumumab	Mice	[99mTc]Tc-(CO)3-His-Annexin A5	Bimodal	3.2, 16	24	1.62	6.9
43	Mitomyci, Ifosfamide, cis-Platinum	Human	[99mTc]Tc-BTAP-Annexin V	Monotonic	N/A	24	4.3	94.5
43	Adriamycin, Bleomycin, Vincristine, Doxorubicin	Human	[99mTc]Tc-BTAP-Annexin V	Monotonic	N/A	24	2.9	0
43	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone	Human	[99mTc]Tc-BTAP-Annexin V	Monotonic	N/A	24	3.2	0
43	Etoposide	Human	[99mTc]Tc-BTAP-Annexin V	Unimodal	14.1	4	3.7	0
44	Doxorubicin	Mice	[99mTc]Tc-Annexin V-117	Bimodal	1.5, 27.9	12	2.07	19.7
38	Paclitaxel	Mice	[99mTc]Tc-C2A-GST	Monotonic	N/A	72	3.27	43.4
40	Paclitaxel	Mice	[99mTc]Tc-His10-Annexin V	Monotonic	N/A	72	3.09	28.2
27	Cyclophosphamide	Rats	[99mTc]Tc-HYNIC-Annexin V	Monotonic	N/A	20	1.56	9.1
30	Paclitaxel	Mice	[99mTc]Tc-HYNIC-Annexin V	Unimodal	3.5	3	1.79	0.6
45	Cyclophosphamide	Mice	Annexin-V FC	Unimodal	85.8	24	1.35	26.8
38	Paclitaxel	Mice	Cleaved caspase-3 FC	Monotonic	N/A	72	35.64	6.7
40	Paclitaxel	Mice	Cleaved caspase-3 FC	Monotonic	N/A	72	22.56	12.2
46	Doxorubicin (1st dose)	Mice	pcFluc-DEVD	Unimodal	342.9	264	23.1	34.2
46	Doxorubicin (2nd dose)	Mice	pcFluc-DEVD	Unimodal	178.7	264	31.6	26.9
47	anti–DR5-Cy5 antibody (1st dose)	Mice	pcFluc-DEVD	Unimodal	6	4	19.5	54.8
47	anti–DR5-Cy5 antibody (2nd dose)	Mice	pcFluc-DEVD	Unimodal	5.6	4	5.88	178.8
47	anti–DR5-Cy5 antibody (3rd dose)	Mice	pcFluc-DEVD	Monotonic	N/A	8	4.21	172.2
47	anti–DR5-Cy5 antibody (subcutaenous tumor)	Mice	pcFluc-DEVD	Unimodal	46.2	8	11.87	56.6
29	Docetaxel	Mice	Z-DEVD-aminoluciferin	Monotonic	N/A	72	3.05	NR
48	Irinotecan	Mice	Z-DEVD-aminoluciferin	Unimodal	35.2	24	2.02	9.8
48	Temozolimide	Mice	Z-DEVD-aminoluciferin	Monotonic	N/A	48	2.13	38.7
	Median (Unimodal Responses) Overall				27.7	24	1.99
	Median (Unimodal Responses) Human				14.1	4	3.7
	Median (Unimodal Responses) Rodent				31.5	24	1.89

Two FWHM values are provided for the bimodal models. FC: flow cytometry, NR: not reported.